nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—CYP3A7—Ifosfamide—germ cell cancer	0.0867	0.181	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Ifosfamide—germ cell cancer	0.0867	0.181	CbGbCtD
Sirolimus—CYP3A5—Ifosfamide—germ cell cancer	0.065	0.136	CbGbCtD
Sirolimus—SLCO1B1—Methotrexate—germ cell cancer	0.0467	0.0973	CbGbCtD
Sirolimus—ABCB1—Dactinomycin—germ cell cancer	0.0358	0.0747	CbGbCtD
Sirolimus—CYP3A5—Etoposide—germ cell cancer	0.0311	0.0648	CbGbCtD
Sirolimus—CYP3A4—Ifosfamide—germ cell cancer	0.0254	0.0529	CbGbCtD
Sirolimus—ABCB1—Vinblastine—germ cell cancer	0.0224	0.0468	CbGbCtD
Sirolimus—ABCB1—Cisplatin—germ cell cancer	0.0206	0.0429	CbGbCtD
Sirolimus—ABCB1—Etoposide—germ cell cancer	0.0202	0.0422	CbGbCtD
Sirolimus—CYP3A4—Vinblastine—germ cell cancer	0.0135	0.0281	CbGbCtD
Sirolimus—ABCB1—Methotrexate—germ cell cancer	0.0134	0.0279	CbGbCtD
Sirolimus—CYP3A4—Etoposide—germ cell cancer	0.0121	0.0253	CbGbCtD
Sirolimus—MTOR—appendage—germ cell cancer	0.00448	0.0421	CbGeAlD
Sirolimus—EIF4E—embryo—germ cell cancer	0.00385	0.0361	CbGeAlD
Sirolimus—EIF4E—telencephalon—germ cell cancer	0.00313	0.0294	CbGeAlD
Sirolimus—EIF4E—gonad—germ cell cancer	0.00261	0.0245	CbGeAlD
Sirolimus—EIF4E—uterus—germ cell cancer	0.00259	0.0243	CbGeAlD
Sirolimus—MTOR—blood vessel—germ cell cancer	0.0025	0.0234	CbGeAlD
Sirolimus—FGF2—trigeminal ganglion—germ cell cancer	0.00243	0.0228	CbGeAlD
Sirolimus—FGF2—eye—germ cell cancer	0.00209	0.0196	CbGeAlD
Sirolimus—EIF4E—endocrine gland—germ cell cancer	0.00197	0.0185	CbGeAlD
Sirolimus—EIF4E—head—germ cell cancer	0.00195	0.0183	CbGeAlD
Sirolimus—EIF4E—testis—germ cell cancer	0.00188	0.0177	CbGeAlD
Sirolimus—FGF2—decidua—germ cell cancer	0.00181	0.017	CbGeAlD
Sirolimus—MTOR—neck—germ cell cancer	0.00179	0.0168	CbGeAlD
Sirolimus—FKBP1A—neck—germ cell cancer	0.00161	0.0151	CbGeAlD
Sirolimus—FGF2—uterus—germ cell cancer	0.00158	0.0148	CbGeAlD
Sirolimus—FGF2—pituitary gland—germ cell cancer	0.00155	0.0146	CbGeAlD
Sirolimus—FGF2—medulla oblongata—germ cell cancer	0.0015	0.0141	CbGeAlD
Sirolimus—MTOR—embryo—germ cell cancer	0.00149	0.014	CbGeAlD
Sirolimus—EIF4E—brain—germ cell cancer	0.00141	0.0133	CbGeAlD
Sirolimus—FGF2—adrenal gland—germ cell cancer	0.00139	0.013	CbGeAlD
Sirolimus—FKBP1A—trigeminal ganglion—germ cell cancer	0.00139	0.013	CbGeAlD
Sirolimus—FGF2—midbrain—germ cell cancer	0.00137	0.0129	CbGeAlD
Sirolimus—MTOR—brainstem—germ cell cancer	0.00136	0.0128	CbGeAlD
Sirolimus—CYP3A4—urine—germ cell cancer	0.00135	0.0127	CbGeAlD
Sirolimus—FGF2—spinal cord—germ cell cancer	0.00134	0.0125	CbGeAlD
Sirolimus—MTOR—eye—germ cell cancer	0.00133	0.0125	CbGeAlD
Sirolimus—MTOR—retina—germ cell cancer	0.00132	0.0124	CbGeAlD
Sirolimus—FGF2—female gonad—germ cell cancer	0.00129	0.0121	CbGeAlD
Sirolimus—MTOR—telencephalon—germ cell cancer	0.00121	0.0114	CbGeAlD
Sirolimus—FKBP1A—eye—germ cell cancer	0.00119	0.0112	CbGeAlD
Sirolimus—SLC47A1—trigeminal ganglion—germ cell cancer	0.00119	0.0112	CbGeAlD
Sirolimus—FKBP1A—retina—germ cell cancer	0.00118	0.0111	CbGeAlD
Sirolimus—MTOR—skin of body—germ cell cancer	0.00116	0.0108	CbGeAlD
Sirolimus—FGF2—testis—germ cell cancer	0.00115	0.0108	CbGeAlD
Sirolimus—FKBP1A—telencephalon—germ cell cancer	0.00109	0.0102	CbGeAlD
Sirolimus—FGF2—cerebellum—germ cell cancer	0.00106	0.00995	CbGeAlD
Sirolimus—SLC47A1—brainstem—germ cell cancer	0.00105	0.0099	CbGeAlD
Sirolimus—FKBP1A—skin of body—germ cell cancer	0.00104	0.00975	CbGeAlD
Sirolimus—FKBP1A—decidua—germ cell cancer	0.00103	0.00969	CbGeAlD
Sirolimus—SLC47A1—eye—germ cell cancer	0.00103	0.00963	CbGeAlD
Sirolimus—MTOR—gonad—germ cell cancer	0.00101	0.00948	CbGeAlD
Sirolimus—MTOR—uterus—germ cell cancer	0.001	0.00942	CbGeAlD
Sirolimus—MTOR—pituitary gland—germ cell cancer	0.000986	0.00925	CbGeAlD
Sirolimus—FKBP1A—gonad—germ cell cancer	0.000909	0.00853	CbGeAlD
Sirolimus—FKBP1A—uterus—germ cell cancer	0.000903	0.00847	CbGeAlD
Sirolimus—SLC47A1—decidua—germ cell cancer	0.000887	0.00832	CbGeAlD
Sirolimus—FKBP1A—pituitary gland—germ cell cancer	0.000887	0.00832	CbGeAlD
Sirolimus—MTOR—adrenal gland—germ cell cancer	0.000881	0.00826	CbGeAlD
Sirolimus—FGF2—brain—germ cell cancer	0.000861	0.00808	CbGeAlD
Sirolimus—FKBP1A—medulla oblongata—germ cell cancer	0.000856	0.00803	CbGeAlD
Sirolimus—MTOR—bone marrow—germ cell cancer	0.000852	0.00799	CbGeAlD
Sirolimus—CYP3A7—endocrine gland—germ cell cancer	0.00085	0.00797	CbGeAlD
Sirolimus—MTOR—spinal cord—germ cell cancer	0.000848	0.00796	CbGeAlD
Sirolimus—FGF2—lymph node—germ cell cancer	0.000832	0.00781	CbGeAlD
Sirolimus—MTOR—female gonad—germ cell cancer	0.000821	0.00771	CbGeAlD
Sirolimus—FKBP1A—adrenal gland—germ cell cancer	0.000792	0.00743	CbGeAlD
Sirolimus—FKBP1A—midbrain—germ cell cancer	0.000782	0.00734	CbGeAlD
Sirolimus—SLC47A1—gonad—germ cell cancer	0.000781	0.00733	CbGeAlD
Sirolimus—SLC47A1—uterus—germ cell cancer	0.000776	0.00728	CbGeAlD
Sirolimus—FKBP1A—bone marrow—germ cell cancer	0.000766	0.00719	CbGeAlD
Sirolimus—MTOR—endocrine gland—germ cell cancer	0.000764	0.00717	CbGeAlD
Sirolimus—FKBP1A—spinal cord—germ cell cancer	0.000763	0.00716	CbGeAlD
Sirolimus—SLC47A1—pituitary gland—germ cell cancer	0.000762	0.00715	CbGeAlD
Sirolimus—MTOR—head—germ cell cancer	0.000754	0.00707	CbGeAlD
Sirolimus—FKBP1A—female gonad—germ cell cancer	0.000739	0.00693	CbGeAlD
Sirolimus—SLC47A1—medulla oblongata—germ cell cancer	0.000735	0.0069	CbGeAlD
Sirolimus—MTOR—testis—germ cell cancer	0.000728	0.00683	CbGeAlD
Sirolimus—FKBP1A—endocrine gland—germ cell cancer	0.000687	0.00645	CbGeAlD
Sirolimus—SLC47A1—adrenal gland—germ cell cancer	0.000681	0.00639	CbGeAlD
Sirolimus—FKBP1A—head—germ cell cancer	0.000678	0.00636	CbGeAlD
Sirolimus—MTOR—cerebellum—germ cell cancer	0.000673	0.00631	CbGeAlD
Sirolimus—SLC47A1—spinal cord—germ cell cancer	0.000656	0.00615	CbGeAlD
Sirolimus—FKBP1A—testis—germ cell cancer	0.000655	0.00615	CbGeAlD
Sirolimus—SLC47A1—female gonad—germ cell cancer	0.000635	0.00596	CbGeAlD
Sirolimus—FKBP1A—cerebellum—germ cell cancer	0.000605	0.00568	CbGeAlD
Sirolimus—SLC47A1—endocrine gland—germ cell cancer	0.00059	0.00554	CbGeAlD
Sirolimus—SLCO1B1—endocrine gland—germ cell cancer	0.000583	0.00547	CbGeAlD
Sirolimus—SLC47A1—head—germ cell cancer	0.000583	0.00547	CbGeAlD
Sirolimus—SLC47A1—testis—germ cell cancer	0.000563	0.00528	CbGeAlD
Sirolimus—MTOR—brain—germ cell cancer	0.000546	0.00513	CbGeAlD
Sirolimus—MTOR—lymph node—germ cell cancer	0.000528	0.00495	CbGeAlD
Sirolimus—SLC47A1—cerebellum—germ cell cancer	0.00052	0.00488	CbGeAlD
Sirolimus—ABCB1—blood vessel—germ cell cancer	0.000519	0.00487	CbGeAlD
Sirolimus—FKBP1A—brain—germ cell cancer	0.000491	0.00461	CbGeAlD
Sirolimus—FKBP1A—lymph node—germ cell cancer	0.000475	0.00446	CbGeAlD
Sirolimus—SLC47A1—brain—germ cell cancer	0.000422	0.00396	CbGeAlD
Sirolimus—SLC47A1—lymph node—germ cell cancer	0.000408	0.00383	CbGeAlD
Sirolimus—CYP3A5—female gonad—germ cell cancer	0.000322	0.00302	CbGeAlD
Sirolimus—ABCB1—trigeminal ganglion—germ cell cancer	0.000321	0.00301	CbGeAlD
Sirolimus—ABCB1—embryo—germ cell cancer	0.00031	0.00291	CbGeAlD
Sirolimus—CYP3A5—endocrine gland—germ cell cancer	0.000299	0.00281	CbGeAlD
Sirolimus—ABCB1—retina—germ cell cancer	0.000274	0.00257	CbGeAlD
Sirolimus—Hypoaesthesia—Etoposide—germ cell cancer	0.000257	0.00118	CcSEcCtD
Sirolimus—Malaise—Ifosfamide—germ cell cancer	0.000257	0.00118	CcSEcCtD
Sirolimus—Urinary tract disorder—Etoposide—germ cell cancer	0.000255	0.00117	CcSEcCtD
Sirolimus—Leukopenia—Ifosfamide—germ cell cancer	0.000255	0.00117	CcSEcCtD
Sirolimus—Polyuria—Methotrexate—germ cell cancer	0.000255	0.00117	CcSEcCtD
Sirolimus—Immune system disorder—Cisplatin—germ cell cancer	0.000255	0.00117	CcSEcCtD
Sirolimus—Abdominal pain—Vinblastine—germ cell cancer	0.000254	0.00117	CcSEcCtD
Sirolimus—Mediastinal disorder—Cisplatin—germ cell cancer	0.000254	0.00117	CcSEcCtD
Sirolimus—Hypotension—Bleomycin—germ cell cancer	0.000254	0.00116	CcSEcCtD
Sirolimus—Oedema—Dactinomycin—germ cell cancer	0.000254	0.00116	CcSEcCtD
Sirolimus—Urethral disorder—Etoposide—germ cell cancer	0.000253	0.00116	CcSEcCtD
Sirolimus—Infection—Dactinomycin—germ cell cancer	0.000252	0.00116	CcSEcCtD
Sirolimus—ABCB1—telencephalon—germ cell cancer	0.000252	0.00236	CbGeAlD
Sirolimus—Palpitations—Ifosfamide—germ cell cancer	0.000252	0.00115	CcSEcCtD
Sirolimus—Hepatic failure—Methotrexate—germ cell cancer	0.000249	0.00114	CcSEcCtD
Sirolimus—Cough—Ifosfamide—germ cell cancer	0.000248	0.00114	CcSEcCtD
Sirolimus—Thrombocytopenia—Dactinomycin—germ cell cancer	0.000248	0.00114	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Bleomycin—germ cell cancer	0.000248	0.00114	CcSEcCtD
Sirolimus—Hypertension—Ifosfamide—germ cell cancer	0.000246	0.00113	CcSEcCtD
Sirolimus—Malnutrition—Cisplatin—germ cell cancer	0.000245	0.00113	CcSEcCtD
Sirolimus—Paraesthesia—Bleomycin—germ cell cancer	0.000244	0.00112	CcSEcCtD
Sirolimus—Dyspnoea—Bleomycin—germ cell cancer	0.000242	0.00111	CcSEcCtD
Sirolimus—Myalgia—Ifosfamide—germ cell cancer	0.000242	0.00111	CcSEcCtD
Sirolimus—Arthralgia—Ifosfamide—germ cell cancer	0.000242	0.00111	CcSEcCtD
Sirolimus—Chest pain—Ifosfamide—germ cell cancer	0.000242	0.00111	CcSEcCtD
Sirolimus—Flatulence—Cisplatin—germ cell cancer	0.000242	0.00111	CcSEcCtD
Sirolimus—Anorexia—Dactinomycin—germ cell cancer	0.000242	0.00111	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.000241	0.0011	CcSEcCtD
Sirolimus—Cardiac disorder—Etoposide—germ cell cancer	0.00024	0.0011	CcSEcCtD
Sirolimus—Discomfort—Ifosfamide—germ cell cancer	0.000239	0.0011	CcSEcCtD
Sirolimus—ABCB1—decidua—germ cell cancer	0.000239	0.00224	CbGeAlD
Sirolimus—Hypersensitivity—Vinblastine—germ cell cancer	0.000237	0.00109	CcSEcCtD
Sirolimus—Dermatitis exfoliative—Methotrexate—germ cell cancer	0.000237	0.00109	CcSEcCtD
Sirolimus—Decreased appetite—Bleomycin—germ cell cancer	0.000236	0.00108	CcSEcCtD
Sirolimus—Muscle spasms—Cisplatin—germ cell cancer	0.000236	0.00108	CcSEcCtD
Sirolimus—Angiopathy—Etoposide—germ cell cancer	0.000234	0.00107	CcSEcCtD
Sirolimus—Confusional state—Ifosfamide—germ cell cancer	0.000234	0.00107	CcSEcCtD
Sirolimus—Immune system disorder—Etoposide—germ cell cancer	0.000233	0.00107	CcSEcCtD
Sirolimus—Mediastinal disorder—Etoposide—germ cell cancer	0.000233	0.00107	CcSEcCtD
Sirolimus—Pain—Bleomycin—germ cell cancer	0.000233	0.00107	CcSEcCtD
Sirolimus—Anaphylactic shock—Ifosfamide—germ cell cancer	0.000232	0.00107	CcSEcCtD
Sirolimus—Oedema—Ifosfamide—germ cell cancer	0.000232	0.00107	CcSEcCtD
Sirolimus—Chills—Etoposide—germ cell cancer	0.000232	0.00106	CcSEcCtD
Sirolimus—Anaphylactoid reaction—Methotrexate—germ cell cancer	0.000231	0.00106	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.000231	0.00106	CcSEcCtD
Sirolimus—Asthenia—Vinblastine—germ cell cancer	0.000231	0.00106	CcSEcCtD
Sirolimus—Infection—Ifosfamide—germ cell cancer	0.000231	0.00106	CcSEcCtD
Sirolimus—Tremor—Cisplatin—germ cell cancer	0.00023	0.00105	CcSEcCtD
Sirolimus—Nervous system disorder—Ifosfamide—germ cell cancer	0.000228	0.00104	CcSEcCtD
Sirolimus—Ill-defined disorder—Cisplatin—germ cell cancer	0.000228	0.00104	CcSEcCtD
Sirolimus—Thrombocytopenia—Ifosfamide—germ cell cancer	0.000228	0.00104	CcSEcCtD
Sirolimus—Anaemia—Cisplatin—germ cell cancer	0.000227	0.00104	CcSEcCtD
Sirolimus—Skin disorder—Ifosfamide—germ cell cancer	0.000226	0.00103	CcSEcCtD
Sirolimus—Hyperhidrosis—Ifosfamide—germ cell cancer	0.000225	0.00103	CcSEcCtD
Sirolimus—CYP3A4—endocrine gland—germ cell cancer	0.000224	0.00211	CbGeAlD
Sirolimus—Feeling abnormal—Bleomycin—germ cell cancer	0.000224	0.00103	CcSEcCtD
Sirolimus—Osteoarthritis—Methotrexate—germ cell cancer	0.000224	0.00103	CcSEcCtD
Sirolimus—Anorexia—Ifosfamide—germ cell cancer	0.000221	0.00102	CcSEcCtD
Sirolimus—Malaise—Cisplatin—germ cell cancer	0.000221	0.00101	CcSEcCtD
Sirolimus—Decreased appetite—Dactinomycin—germ cell cancer	0.00022	0.00101	CcSEcCtD
Sirolimus—Diarrhoea—Vinblastine—germ cell cancer	0.00022	0.00101	CcSEcCtD
Sirolimus—Leukopenia—Cisplatin—germ cell cancer	0.00022	0.00101	CcSEcCtD
Sirolimus—Back pain—Etoposide—germ cell cancer	0.000218	0.000997	CcSEcCtD
Sirolimus—Hypotension—Ifosfamide—germ cell cancer	0.000217	0.000996	CcSEcCtD
Sirolimus—Pain—Dactinomycin—germ cell cancer	0.000217	0.000994	CcSEcCtD
Sirolimus—Muscle spasms—Etoposide—germ cell cancer	0.000216	0.000991	CcSEcCtD
Sirolimus—Body temperature increased—Bleomycin—germ cell cancer	0.000215	0.000985	CcSEcCtD
Sirolimus—Dizziness—Vinblastine—germ cell cancer	0.000213	0.000976	CcSEcCtD
Sirolimus—Mood swings—Methotrexate—germ cell cancer	0.000212	0.000971	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.000212	0.000971	CcSEcCtD
Sirolimus—ABCB1—gonad—germ cell cancer	0.00021	0.00197	CbGeAlD
Sirolimus—Myalgia—Cisplatin—germ cell cancer	0.000209	0.000958	CcSEcCtD
Sirolimus—Feeling abnormal—Dactinomycin—germ cell cancer	0.000209	0.000958	CcSEcCtD
Sirolimus—ABCB1—uterus—germ cell cancer	0.000209	0.00196	CbGeAlD
Sirolimus—Paraesthesia—Ifosfamide—germ cell cancer	0.000209	0.000957	CcSEcCtD
Sirolimus—Ill-defined disorder—Etoposide—germ cell cancer	0.000209	0.000957	CcSEcCtD
Sirolimus—Anxiety—Cisplatin—germ cell cancer	0.000208	0.000955	CcSEcCtD
Sirolimus—Anaemia—Etoposide—germ cell cancer	0.000208	0.000953	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.000208	0.000952	CcSEcCtD
Sirolimus—Gastrointestinal pain—Dactinomycin—germ cell cancer	0.000207	0.000951	CcSEcCtD
Sirolimus—Dyspnoea—Ifosfamide—germ cell cancer	0.000207	0.00095	CcSEcCtD
Sirolimus—Somnolence—Ifosfamide—germ cell cancer	0.000207	0.000947	CcSEcCtD
Sirolimus—Liver function test abnormal—Methotrexate—germ cell cancer	0.000206	0.000947	CcSEcCtD
Sirolimus—Discomfort—Cisplatin—germ cell cancer	0.000206	0.000947	CcSEcCtD
Sirolimus—ABCB1—pituitary gland—germ cell cancer	0.000205	0.00192	CbGeAlD
Sirolimus—Vomiting—Vinblastine—germ cell cancer	0.000205	0.000938	CcSEcCtD
Sirolimus—Malaise—Etoposide—germ cell cancer	0.000203	0.00093	CcSEcCtD
Sirolimus—Breast disorder—Methotrexate—germ cell cancer	0.000202	0.000927	CcSEcCtD
Sirolimus—Decreased appetite—Ifosfamide—germ cell cancer	0.000202	0.000926	CcSEcCtD
Sirolimus—Headache—Vinblastine—germ cell cancer	0.000202	0.000925	CcSEcCtD
Sirolimus—Leukopenia—Etoposide—germ cell cancer	0.000201	0.000923	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Ifosfamide—germ cell cancer	0.000201	0.00092	CcSEcCtD
Sirolimus—Body temperature increased—Dactinomycin—germ cell cancer	0.0002	0.000919	CcSEcCtD
Sirolimus—Abdominal pain—Dactinomycin—germ cell cancer	0.0002	0.000919	CcSEcCtD
Sirolimus—Oedema—Cisplatin—germ cell cancer	0.0002	0.000918	CcSEcCtD
Sirolimus—Anaphylactic shock—Cisplatin—germ cell cancer	0.0002	0.000918	CcSEcCtD
Sirolimus—Hypersensitivity—Bleomycin—germ cell cancer	0.0002	0.000918	CcSEcCtD
Sirolimus—Infection—Cisplatin—germ cell cancer	0.000199	0.000912	CcSEcCtD
Sirolimus—Pain—Ifosfamide—germ cell cancer	0.000199	0.000911	CcSEcCtD
Sirolimus—Constipation—Ifosfamide—germ cell cancer	0.000199	0.000911	CcSEcCtD
Sirolimus—ABCB1—medulla oblongata—germ cell cancer	0.000198	0.00186	CbGeAlD
Sirolimus—Loss of consciousness—Etoposide—germ cell cancer	0.000198	0.000906	CcSEcCtD
Sirolimus—Nervous system disorder—Cisplatin—germ cell cancer	0.000196	0.000901	CcSEcCtD
Sirolimus—Cough—Etoposide—germ cell cancer	0.000196	0.0009	CcSEcCtD
Sirolimus—Thrombocytopenia—Cisplatin—germ cell cancer	0.000196	0.000899	CcSEcCtD
Sirolimus—Tachycardia—Cisplatin—germ cell cancer	0.000196	0.000896	CcSEcCtD
Sirolimus—Asthenia—Bleomycin—germ cell cancer	0.000195	0.000894	CcSEcCtD
Sirolimus—Skin disorder—Cisplatin—germ cell cancer	0.000195	0.000892	CcSEcCtD
Sirolimus—Hypertension—Etoposide—germ cell cancer	0.000194	0.00089	CcSEcCtD
Sirolimus—Hyperhidrosis—Cisplatin—germ cell cancer	0.000194	0.000888	CcSEcCtD
Sirolimus—Asthma—Methotrexate—germ cell cancer	0.000193	0.000886	CcSEcCtD
Sirolimus—Pruritus—Bleomycin—germ cell cancer	0.000192	0.000882	CcSEcCtD
Sirolimus—Feeling abnormal—Ifosfamide—germ cell cancer	0.000191	0.000878	CcSEcCtD
Sirolimus—Chest pain—Etoposide—germ cell cancer	0.000191	0.000878	CcSEcCtD
Sirolimus—Nausea—Vinblastine—germ cell cancer	0.000191	0.000877	CcSEcCtD
Sirolimus—Anorexia—Cisplatin—germ cell cancer	0.000191	0.000876	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	0.00019	0.000872	CcSEcCtD
Sirolimus—Gastrointestinal pain—Ifosfamide—germ cell cancer	0.00019	0.000871	CcSEcCtD
Sirolimus—Pancreatitis—Methotrexate—germ cell cancer	0.00019	0.000869	CcSEcCtD
Sirolimus—Discomfort—Etoposide—germ cell cancer	0.000189	0.000867	CcSEcCtD
Sirolimus—Hypotension—Cisplatin—germ cell cancer	0.000187	0.000858	CcSEcCtD
Sirolimus—Hypersensitivity—Dactinomycin—germ cell cancer	0.000187	0.000857	CcSEcCtD
Sirolimus—Confusional state—Etoposide—germ cell cancer	0.000185	0.000848	CcSEcCtD
Sirolimus—Abdominal pain—Ifosfamide—germ cell cancer	0.000184	0.000842	CcSEcCtD
Sirolimus—Body temperature increased—Ifosfamide—germ cell cancer	0.000184	0.000842	CcSEcCtD
Sirolimus—Pancytopenia—Methotrexate—germ cell cancer	0.000184	0.000842	CcSEcCtD
Sirolimus—Anaphylactic shock—Etoposide—germ cell cancer	0.000184	0.000841	CcSEcCtD
Sirolimus—ABCB1—adrenal gland—germ cell cancer	0.000183	0.00172	CbGeAlD
Sirolimus—Musculoskeletal discomfort—Cisplatin—germ cell cancer	0.000183	0.000837	CcSEcCtD
Sirolimus—Infection—Etoposide—germ cell cancer	0.000182	0.000836	CcSEcCtD
Sirolimus—Asthenia—Dactinomycin—germ cell cancer	0.000182	0.000834	CcSEcCtD
Sirolimus—ABCB1—midbrain—germ cell cancer	0.000181	0.0017	CbGeAlD
Sirolimus—Neutropenia—Methotrexate—germ cell cancer	0.000181	0.000829	CcSEcCtD
Sirolimus—Dysuria—Methotrexate—germ cell cancer	0.000181	0.000829	CcSEcCtD
Sirolimus—Paraesthesia—Cisplatin—germ cell cancer	0.00018	0.000825	CcSEcCtD
Sirolimus—Thrombocytopenia—Etoposide—germ cell cancer	0.00018	0.000824	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Methotrexate—germ cell cancer	0.00018	0.000824	CcSEcCtD
Sirolimus—Tachycardia—Etoposide—germ cell cancer	0.000179	0.000821	CcSEcCtD
Sirolimus—Dyspnoea—Cisplatin—germ cell cancer	0.000179	0.000819	CcSEcCtD
Sirolimus—Skin disorder—Etoposide—germ cell cancer	0.000178	0.000817	CcSEcCtD
Sirolimus—Erectile dysfunction—Methotrexate—germ cell cancer	0.000178	0.000816	CcSEcCtD
Sirolimus—Hyperhidrosis—Etoposide—germ cell cancer	0.000177	0.000813	CcSEcCtD
Sirolimus—ABCB1—bone marrow—germ cell cancer	0.000177	0.00166	CbGeAlD
Sirolimus—ABCB1—spinal cord—germ cell cancer	0.000176	0.00166	CbGeAlD
Sirolimus—Anorexia—Etoposide—germ cell cancer	0.000175	0.000802	CcSEcCtD
Sirolimus—Decreased appetite—Cisplatin—germ cell cancer	0.000174	0.000798	CcSEcCtD
Sirolimus—Diarrhoea—Dactinomycin—germ cell cancer	0.000173	0.000795	CcSEcCtD
Sirolimus—Pneumonia—Methotrexate—germ cell cancer	0.000173	0.000795	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Cisplatin—germ cell cancer	0.000173	0.000793	CcSEcCtD
Sirolimus—Vomiting—Bleomycin—germ cell cancer	0.000173	0.000793	CcSEcCtD
Sirolimus—Infestation NOS—Methotrexate—germ cell cancer	0.000172	0.00079	CcSEcCtD
Sirolimus—Infestation—Methotrexate—germ cell cancer	0.000172	0.00079	CcSEcCtD
Sirolimus—Hypotension—Etoposide—germ cell cancer	0.000171	0.000786	CcSEcCtD
Sirolimus—Rash—Bleomycin—germ cell cancer	0.000171	0.000786	CcSEcCtD
Sirolimus—Pain—Cisplatin—germ cell cancer	0.000171	0.000785	CcSEcCtD
Sirolimus—Dermatitis—Bleomycin—germ cell cancer	0.000171	0.000785	CcSEcCtD
Sirolimus—Hypersensitivity—Ifosfamide—germ cell cancer	0.000171	0.000785	CcSEcCtD
Sirolimus—ABCB1—female gonad—germ cell cancer	0.000171	0.0016	CbGeAlD
Sirolimus—Stomatitis—Methotrexate—germ cell cancer	0.000168	0.00077	CcSEcCtD
Sirolimus—Conjunctivitis—Methotrexate—germ cell cancer	0.000168	0.000768	CcSEcCtD
Sirolimus—Asthenia—Ifosfamide—germ cell cancer	0.000167	0.000764	CcSEcCtD
Sirolimus—Sweating—Methotrexate—germ cell cancer	0.000165	0.000758	CcSEcCtD
Sirolimus—Feeling abnormal—Cisplatin—germ cell cancer	0.000165	0.000757	CcSEcCtD
Sirolimus—Paraesthesia—Etoposide—germ cell cancer	0.000165	0.000756	CcSEcCtD
Sirolimus—Pruritus—Ifosfamide—germ cell cancer	0.000164	0.000754	CcSEcCtD
Sirolimus—Haematuria—Methotrexate—germ cell cancer	0.000164	0.000753	CcSEcCtD
Sirolimus—Dyspnoea—Etoposide—germ cell cancer	0.000164	0.00075	CcSEcCtD
Sirolimus—Somnolence—Etoposide—germ cell cancer	0.000163	0.000748	CcSEcCtD
Sirolimus—Hepatobiliary disease—Methotrexate—germ cell cancer	0.000163	0.000747	CcSEcCtD
Sirolimus—Epistaxis—Methotrexate—germ cell cancer	0.000163	0.000745	CcSEcCtD
Sirolimus—Nausea—Bleomycin—germ cell cancer	0.000161	0.00074	CcSEcCtD
Sirolimus—Vomiting—Dactinomycin—germ cell cancer	0.000161	0.000739	CcSEcCtD
Sirolimus—Rash—Dactinomycin—germ cell cancer	0.00016	0.000733	CcSEcCtD
Sirolimus—Decreased appetite—Etoposide—germ cell cancer	0.00016	0.000731	CcSEcCtD
Sirolimus—Diarrhoea—Ifosfamide—germ cell cancer	0.000159	0.000729	CcSEcCtD
Sirolimus—ABCB1—endocrine gland—germ cell cancer	0.000159	0.00149	CbGeAlD
Sirolimus—Gastrointestinal disorder—Etoposide—germ cell cancer	0.000158	0.000726	CcSEcCtD
Sirolimus—Body temperature increased—Cisplatin—germ cell cancer	0.000158	0.000726	CcSEcCtD
Sirolimus—Constipation—Etoposide—germ cell cancer	0.000157	0.00072	CcSEcCtD
Sirolimus—Pain—Etoposide—germ cell cancer	0.000157	0.00072	CcSEcCtD
Sirolimus—ABCB1—head—germ cell cancer	0.000157	0.00147	CbGeAlD
Sirolimus—Haemoglobin—Methotrexate—germ cell cancer	0.000156	0.000713	CcSEcCtD
Sirolimus—Haemorrhage—Methotrexate—germ cell cancer	0.000155	0.000709	CcSEcCtD
Sirolimus—Dizziness—Ifosfamide—germ cell cancer	0.000154	0.000705	CcSEcCtD
Sirolimus—Pharyngitis—Methotrexate—germ cell cancer	0.000154	0.000704	CcSEcCtD
Sirolimus—Urinary tract disorder—Methotrexate—germ cell cancer	0.000153	0.000701	CcSEcCtD
Sirolimus—Urethral disorder—Methotrexate—germ cell cancer	0.000152	0.000695	CcSEcCtD
Sirolimus—ABCB1—testis—germ cell cancer	0.000152	0.00142	CbGeAlD
Sirolimus—Feeling abnormal—Etoposide—germ cell cancer	0.000151	0.000693	CcSEcCtD
Sirolimus—Nausea—Dactinomycin—germ cell cancer	0.000151	0.000691	CcSEcCtD
Sirolimus—FGF2—B Cell Activation—KIT—germ cell cancer	0.00015	0.000768	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Etoposide—germ cell cancer	0.00015	0.000688	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—germ cell cancer	0.000149	0.000684	CcSEcCtD
Sirolimus—EIF4E—BDNF signaling pathway—HRAS—germ cell cancer	0.000149	0.000761	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—FGFR3—germ cell cancer	0.000148	0.000758	CbGpPWpGaD
Sirolimus—Vomiting—Ifosfamide—germ cell cancer	0.000148	0.000677	CcSEcCtD
Sirolimus—Hypersensitivity—Cisplatin—germ cell cancer	0.000148	0.000677	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—FGF4—germ cell cancer	0.000147	0.000749	CbGpPWpGaD
Sirolimus—Rash—Ifosfamide—germ cell cancer	0.000147	0.000672	CcSEcCtD
Sirolimus—Dermatitis—Ifosfamide—germ cell cancer	0.000146	0.000671	CcSEcCtD
Sirolimus—MTOR—TSH signaling pathway—MYC—germ cell cancer	0.000146	0.000747	CbGpPWpGaD
Sirolimus—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—germ cell cancer	0.000145	0.000741	CbGpPWpGaD
Sirolimus—Abdominal pain—Etoposide—germ cell cancer	0.000145	0.000665	CcSEcCtD
Sirolimus—Body temperature increased—Etoposide—germ cell cancer	0.000145	0.000665	CcSEcCtD
Sirolimus—MTOR—Signaling by SCF-KIT—KIT—germ cell cancer	0.000145	0.000739	CbGpPWpGaD
Sirolimus—Tinnitus—Methotrexate—germ cell cancer	0.000144	0.000661	CcSEcCtD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—KIT—germ cell cancer	0.000144	0.000735	CbGpPWpGaD
Sirolimus—Asthenia—Cisplatin—germ cell cancer	0.000144	0.000659	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—germ cell cancer	0.000144	0.000658	CcSEcCtD
Sirolimus—MTOR—Regulation of Telomerase—MYC—germ cell cancer	0.000143	0.000729	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—FGFR3—germ cell cancer	0.000142	0.000724	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—FGFR3—germ cell cancer	0.000141	0.00072	CbGpPWpGaD
Sirolimus—MTOR—ErbB Signaling Pathway—TP53—germ cell cancer	0.000141	0.00072	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—FGFR3—germ cell cancer	0.00014	0.000717	CbGpPWpGaD
Sirolimus—Angiopathy—Methotrexate—germ cell cancer	0.00014	0.000644	CcSEcCtD
Sirolimus—FGF2—Neural Crest Differentiation—MYC—germ cell cancer	0.00014	0.000716	CbGpPWpGaD
Sirolimus—ABCB1—cerebellum—germ cell cancer	0.00014	0.00131	CbGeAlD
Sirolimus—Immune system disorder—Methotrexate—germ cell cancer	0.00014	0.000641	CcSEcCtD
Sirolimus—MTOR—DAP12 signaling—FGFR3—germ cell cancer	0.00014	0.000713	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—H2AFZ—germ cell cancer	0.00014	0.000713	CbGpPWpGaD
Sirolimus—Mediastinal disorder—Methotrexate—germ cell cancer	0.000139	0.000639	CcSEcCtD
Sirolimus—FKBP1A—Disease—SLC2A3—germ cell cancer	0.000139	0.000711	CbGpPWpGaD
Sirolimus—Chills—Methotrexate—germ cell cancer	0.000139	0.000637	CcSEcCtD
Sirolimus—MTOR—Downstream signaling of activated FGFR—KIT—germ cell cancer	0.000138	0.000707	CbGpPWpGaD
Sirolimus—Nausea—Ifosfamide—germ cell cancer	0.000138	0.000633	CcSEcCtD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—germ cell cancer	0.000138	0.000703	CbGpPWpGaD
Sirolimus—Diarrhoea—Cisplatin—germ cell cancer	0.000137	0.000628	CcSEcCtD
Sirolimus—EIF4E—Insulin Signaling—HRAS—germ cell cancer	0.000137	0.0007	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—KIT—germ cell cancer	0.000136	0.000696	CbGpPWpGaD
Sirolimus—Hypersensitivity—Etoposide—germ cell cancer	0.000135	0.00062	CcSEcCtD
Sirolimus—MTOR—ErbB Signaling Pathway—HRAS—germ cell cancer	0.000135	0.000688	CbGpPWpGaD
Sirolimus—Malnutrition—Methotrexate—germ cell cancer	0.000135	0.000618	CcSEcCtD
Sirolimus—FKBP1A—Spinal Cord Injury—TP53—germ cell cancer	0.000134	0.000685	CbGpPWpGaD
Sirolimus—Asthenia—Etoposide—germ cell cancer	0.000132	0.000604	CcSEcCtD
Sirolimus—MTOR—DAP12 interactions—FGFR3—germ cell cancer	0.000131	0.000671	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR3—germ cell cancer	0.000131	0.000671	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—FGFR3—germ cell cancer	0.000131	0.000671	CbGpPWpGaD
Sirolimus—Back pain—Methotrexate—germ cell cancer	0.00013	0.000597	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR—FGFR3—germ cell cancer	0.00013	0.000665	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—KIT—germ cell cancer	0.00013	0.000665	CbGpPWpGaD
Sirolimus—Pruritus—Etoposide—germ cell cancer	0.00013	0.000595	CcSEcCtD
Sirolimus—MTOR—Signaling by FGFR—KIT—germ cell cancer	0.00013	0.000661	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—FGFR3—germ cell cancer	0.000129	0.000659	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—KIT—germ cell cancer	0.000129	0.000658	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—FGFR3—germ cell cancer	0.000129	0.000656	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—KIT—germ cell cancer	0.000128	0.000655	CbGpPWpGaD
Sirolimus—Vomiting—Cisplatin—germ cell cancer	0.000127	0.000584	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—PVRL2—germ cell cancer	0.000127	0.000649	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—germ cell cancer	0.000126	0.000646	CbGpPWpGaD
Sirolimus—FGF2—IRS-mediated signalling—HRAS—germ cell cancer	0.000126	0.000645	CbGpPWpGaD
Sirolimus—Rash—Cisplatin—germ cell cancer	0.000126	0.000579	CcSEcCtD
Sirolimus—Dermatitis—Cisplatin—germ cell cancer	0.000126	0.000579	CcSEcCtD
Sirolimus—Diarrhoea—Etoposide—germ cell cancer	0.000126	0.000576	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—germ cell cancer	0.000125	0.000573	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—germ cell cancer	0.000124	0.000571	CcSEcCtD
Sirolimus—FGF2—IRS-related events—HRAS—germ cell cancer	0.000123	0.000628	CbGpPWpGaD
Sirolimus—FGF2—IRS-related events triggered by IGF1R—HRAS—germ cell cancer	0.000122	0.000622	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—FGFR3—germ cell cancer	0.000122	0.000621	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—germ cell cancer	0.000122	0.000621	CbGpPWpGaD
Sirolimus—Malaise—Methotrexate—germ cell cancer	0.000121	0.000557	CcSEcCtD
Sirolimus—Dizziness—Etoposide—germ cell cancer	0.000121	0.000556	CcSEcCtD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—germ cell cancer	0.000121	0.000616	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—KIT—germ cell cancer	0.000121	0.000616	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—KIT—germ cell cancer	0.000121	0.000616	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—FGFR3—germ cell cancer	0.000121	0.000616	CbGpPWpGaD
Sirolimus—Leukopenia—Methotrexate—germ cell cancer	0.000121	0.000553	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—KITLG—germ cell cancer	0.00012	0.000615	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	0.00012	0.000615	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—KIT—germ cell cancer	0.00012	0.000611	CbGpPWpGaD
Sirolimus—Nausea—Cisplatin—germ cell cancer	0.000119	0.000546	CcSEcCtD
Sirolimus—FGF2—Insulin receptor signalling cascade—HRAS—germ cell cancer	0.000119	0.000606	CbGpPWpGaD
Sirolimus—FGF2—IGF1R signaling cascade—HRAS—germ cell cancer	0.000119	0.000606	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	0.000119	0.000606	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—KIT—germ cell cancer	0.000119	0.000605	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—FGF4—germ cell cancer	0.000118	0.000603	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—KIT—germ cell cancer	0.000118	0.000603	CbGpPWpGaD
Sirolimus—Cough—Methotrexate—germ cell cancer	0.000118	0.000539	CcSEcCtD
Sirolimus—Vomiting—Etoposide—germ cell cancer	0.000117	0.000535	CcSEcCtD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—germ cell cancer	0.000116	0.000594	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—germ cell cancer	0.000116	0.000594	CbGpPWpGaD
Sirolimus—MTOR—AMPK Signaling—TP53—germ cell cancer	0.000116	0.000592	CbGpPWpGaD
Sirolimus—Rash—Etoposide—germ cell cancer	0.000116	0.000531	CcSEcCtD
Sirolimus—Dermatitis—Etoposide—germ cell cancer	0.000116	0.00053	CcSEcCtD
Sirolimus—Headache—Etoposide—germ cell cancer	0.000115	0.000527	CcSEcCtD
Sirolimus—MTOR—TSH signaling pathway—HRAS—germ cell cancer	0.000115	0.000586	CbGpPWpGaD
Sirolimus—MTOR—mTOR signaling pathway—HRAS—germ cell cancer	0.000115	0.000586	CbGpPWpGaD
Sirolimus—Myalgia—Methotrexate—germ cell cancer	0.000115	0.000526	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—germ cell cancer	0.000115	0.000526	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—germ cell cancer	0.000115	0.000526	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	0.000114	0.000522	CcSEcCtD
Sirolimus—ABCB1—brain—germ cell cancer	0.000114	0.00107	CbGeAlD
Sirolimus—Discomfort—Methotrexate—germ cell cancer	0.000113	0.000519	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—FGF4—germ cell cancer	0.000113	0.000576	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—KIT—germ cell cancer	0.000112	0.00057	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	0.000111	0.000567	CbGpPWpGaD
Sirolimus—Confusional state—Methotrexate—germ cell cancer	0.000111	0.000508	CcSEcCtD
Sirolimus—FGF2—Signaling by NGF—KIT—germ cell cancer	0.000111	0.000566	CbGpPWpGaD
Sirolimus—Anaphylactic shock—Methotrexate—germ cell cancer	0.00011	0.000504	CcSEcCtD
Sirolimus—ABCB1—lymph node—germ cell cancer	0.00011	0.00103	CbGeAlD
Sirolimus—MTOR—CDC42 signaling events—HRAS—germ cell cancer	0.00011	0.000559	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—AVP—germ cell cancer	0.000109	0.000558	CbGpPWpGaD
Sirolimus—Infection—Methotrexate—germ cell cancer	0.000109	0.000501	CcSEcCtD
Sirolimus—Nausea—Etoposide—germ cell cancer	0.000109	0.0005	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—FGF4—germ cell cancer	0.000108	0.000553	CbGpPWpGaD
Sirolimus—Nervous system disorder—Methotrexate—germ cell cancer	0.000108	0.000494	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—germ cell cancer	0.000108	0.000493	CcSEcCtD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—germ cell cancer	0.000107	0.000546	CbGpPWpGaD
Sirolimus—Skin disorder—Methotrexate—germ cell cancer	0.000107	0.00049	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—germ cell cancer	0.000106	0.000487	CcSEcCtD
Sirolimus—FGF2—Disease—SLC2A3—germ cell cancer	0.000106	0.000539	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—H2AFZ—germ cell cancer	0.000105	0.000535	CbGpPWpGaD
Sirolimus—Anorexia—Methotrexate—germ cell cancer	0.000105	0.00048	CcSEcCtD
Sirolimus—FGF2—Immune System—PVRL2—germ cell cancer	0.000104	0.000531	CbGpPWpGaD
Sirolimus—MTOR—Leptin signaling pathway—HRAS—germ cell cancer	0.000104	0.000529	CbGpPWpGaD
Sirolimus—Hypotension—Methotrexate—germ cell cancer	0.000103	0.000471	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	0.000102	0.000519	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Methotrexate—germ cell cancer	0.0001	0.000459	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—germ cell cancer	9.94e-05	0.000456	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—germ cell cancer	9.87e-05	0.000453	CcSEcCtD
Sirolimus—FGF2—Signaling by Insulin receptor—HRAS—germ cell cancer	9.85e-05	0.000503	CbGpPWpGaD
Sirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—germ cell cancer	9.84e-05	0.000503	CbGpPWpGaD
Sirolimus—Dyspnoea—Methotrexate—germ cell cancer	9.8e-05	0.000449	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—germ cell cancer	9.77e-05	0.000448	CcSEcCtD
Sirolimus—EIF4E—Immune System—KITLG—germ cell cancer	9.7e-05	0.000495	CbGpPWpGaD
Sirolimus—Dyspepsia—Methotrexate—germ cell cancer	9.68e-05	0.000444	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—germ cell cancer	9.56e-05	0.000438	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—germ cell cancer	9.49e-05	0.000435	CcSEcCtD
Sirolimus—Pain—Methotrexate—germ cell cancer	9.4e-05	0.000431	CcSEcCtD
Sirolimus—MTOR—IRS-mediated signalling—HRAS—germ cell cancer	9.38e-05	0.000479	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KITLG—germ cell cancer	9.26e-05	0.000473	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SCNN1A—germ cell cancer	9.21e-05	0.000471	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	9.12e-05	0.000466	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events—HRAS—germ cell cancer	9.12e-05	0.000466	CbGpPWpGaD
Sirolimus—Feeling abnormal—Methotrexate—germ cell cancer	9.06e-05	0.000415	CcSEcCtD
Sirolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—germ cell cancer	9.04e-05	0.000462	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Methotrexate—germ cell cancer	8.99e-05	0.000412	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—FGFR3—germ cell cancer	8.95e-05	0.000457	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—OXT—germ cell cancer	8.94e-05	0.000457	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KITLG—germ cell cancer	8.89e-05	0.000454	CbGpPWpGaD
Sirolimus—MTOR—Insulin receptor signalling cascade—HRAS—germ cell cancer	8.8e-05	0.00045	CbGpPWpGaD
Sirolimus—MTOR—IGF1R signaling cascade—HRAS—germ cell cancer	8.8e-05	0.00045	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—HRAS—germ cell cancer	8.76e-05	0.000447	CbGpPWpGaD
Sirolimus—Body temperature increased—Methotrexate—germ cell cancer	8.69e-05	0.000398	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—germ cell cancer	8.69e-05	0.000398	CcSEcCtD
Sirolimus—FGF2—Signaling by SCF-KIT—HRAS—germ cell cancer	8.43e-05	0.00043	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	8.42e-05	0.00043	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—FGF4—germ cell cancer	8.36e-05	0.000427	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—germ cell cancer	8.28e-05	0.000423	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—KIT—germ cell cancer	8.22e-05	0.00042	CbGpPWpGaD
Sirolimus—Hypersensitivity—Methotrexate—germ cell cancer	8.1e-05	0.000371	CcSEcCtD
Sirolimus—FGF2—Downstream signaling of activated FGFR—HRAS—germ cell cancer	8.06e-05	0.000412	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—FGF4—germ cell cancer	8.03e-05	0.00041	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—FGF4—germ cell cancer	8e-05	0.000408	CbGpPWpGaD
Sirolimus—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—germ cell cancer	7.99e-05	0.000408	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—HRAS—germ cell cancer	7.94e-05	0.000405	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—germ cell cancer	7.92e-05	0.000404	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—HRAS—germ cell cancer	7.92e-05	0.000404	CbGpPWpGaD
Sirolimus—Asthenia—Methotrexate—germ cell cancer	7.89e-05	0.000362	CcSEcCtD
Sirolimus—MTOR—Disease—SLC2A3—germ cell cancer	7.83e-05	0.0004	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—germ cell cancer	7.8e-05	0.000398	CbGpPWpGaD
Sirolimus—Pruritus—Methotrexate—germ cell cancer	7.78e-05	0.000357	CcSEcCtD
Sirolimus—MTOR—Immune System—PVRL2—germ cell cancer	7.71e-05	0.000394	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—FGF4—germ cell cancer	7.63e-05	0.00039	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—HRAS—germ cell cancer	7.58e-05	0.000387	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—HRAS—germ cell cancer	7.54e-05	0.000385	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—MYC—germ cell cancer	7.54e-05	0.000385	CbGpPWpGaD
Sirolimus—Diarrhoea—Methotrexate—germ cell cancer	7.52e-05	0.000345	CcSEcCtD
Sirolimus—FGF2—Signaling by ERBB2—HRAS—germ cell cancer	7.51e-05	0.000383	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—HRAS—germ cell cancer	7.47e-05	0.000381	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—HRAS—germ cell cancer	7.36e-05	0.000376	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	7.36e-05	0.000376	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—HRAS—germ cell cancer	7.31e-05	0.000373	CbGpPWpGaD
Sirolimus—Dizziness—Methotrexate—germ cell cancer	7.27e-05	0.000333	CcSEcCtD
Sirolimus—EIF4E—Immune System—FGFR3—germ cell cancer	7.21e-05	0.000368	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—H2AFZ—germ cell cancer	7.14e-05	0.000365	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—HRAS—germ cell cancer	7.03e-05	0.000359	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	7.03e-05	0.000359	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—HRAS—germ cell cancer	7.03e-05	0.000359	CbGpPWpGaD
Sirolimus—Vomiting—Methotrexate—germ cell cancer	6.99e-05	0.00032	CcSEcCtD
Sirolimus—FGF2—Signaling by EGFR—HRAS—germ cell cancer	6.96e-05	0.000356	CbGpPWpGaD
Sirolimus—Rash—Methotrexate—germ cell cancer	6.93e-05	0.000318	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—germ cell cancer	6.92e-05	0.000317	CcSEcCtD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	6.91e-05	0.000353	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—HRAS—germ cell cancer	6.9e-05	0.000352	CbGpPWpGaD
Sirolimus—Headache—Methotrexate—germ cell cancer	6.89e-05	0.000316	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—FGFR3—germ cell cancer	6.88e-05	0.000351	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—HRAS—germ cell cancer	6.87e-05	0.000351	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KITLG—germ cell cancer	6.87e-05	0.000351	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—H2AFZ—germ cell cancer	6.82e-05	0.000348	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—KIT—germ cell cancer	6.62e-05	0.000338	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—FGFR3—germ cell cancer	6.61e-05	0.000337	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KITLG—germ cell cancer	6.6e-05	0.000337	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KITLG—germ cell cancer	6.57e-05	0.000335	CbGpPWpGaD
Sirolimus—FGF2—Immune System—FGF4—germ cell cancer	6.56e-05	0.000335	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—OXT—germ cell cancer	6.56e-05	0.000335	CbGpPWpGaD
Sirolimus—Nausea—Methotrexate—germ cell cancer	6.53e-05	0.000299	CcSEcCtD
Sirolimus—FGF2—B Cell Activation—HRAS—germ cell cancer	6.5e-05	0.000332	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KIT—germ cell cancer	6.32e-05	0.000323	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KITLG—germ cell cancer	6.27e-05	0.00032	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—HRAS—germ cell cancer	6.26e-05	0.000319	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	6.22e-05	0.000318	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—germ cell cancer	6.19e-05	0.000316	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—HRAS—germ cell cancer	6.15e-05	0.000314	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AVP—germ cell cancer	6.13e-05	0.000313	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KIT—germ cell cancer	6.07e-05	0.00031	CbGpPWpGaD
Sirolimus—FGF2—Disease—FGF4—germ cell cancer	6.06e-05	0.000309	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	6.03e-05	0.000308	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—germ cell cancer	5.99e-05	0.000306	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	5.94e-05	0.000303	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—HRAS—germ cell cancer	5.89e-05	0.000301	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—HRAS—germ cell cancer	5.65e-05	0.000289	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SLC2A3—germ cell cancer	5.64e-05	0.000288	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—HRAS—germ cell cancer	5.63e-05	0.000287	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FGF4—germ cell cancer	5.6e-05	0.000286	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—HRAS—germ cell cancer	5.6e-05	0.000286	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	5.6e-05	0.000286	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—HRAS—germ cell cancer	5.57e-05	0.000284	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SLC22A3—germ cell cancer	5.55e-05	0.000284	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—AVP—germ cell cancer	5.55e-05	0.000284	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—HRAS—germ cell cancer	5.54e-05	0.000283	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	5.46e-05	0.000279	CbGpPWpGaD
Sirolimus—FGF2—Disease—H2AFZ—germ cell cancer	5.41e-05	0.000276	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KITLG—germ cell cancer	5.39e-05	0.000275	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—HRAS—germ cell cancer	5.21e-05	0.000266	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	5.21e-05	0.000266	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—HRAS—germ cell cancer	5.21e-05	0.000266	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SLC2A3—germ cell cancer	5.18e-05	0.000264	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—HRAS—germ cell cancer	5.17e-05	0.000264	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—germ cell cancer	5.12e-05	0.000262	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—FGFR3—germ cell cancer	5.11e-05	0.000261	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—HRAS—germ cell cancer	5.1e-05	0.00026	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SLC22A3—germ cell cancer	5.1e-05	0.00026	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—H2AFZ—germ cell cancer	5e-05	0.000255	CbGpPWpGaD
Sirolimus—FGF2—Disease—KITLG—germ cell cancer	4.98e-05	0.000254	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—OXT—germ cell cancer	4.97e-05	0.000254	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—FGFR3—germ cell cancer	4.9e-05	0.00025	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—FGFR3—germ cell cancer	4.88e-05	0.000249	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FGF4—germ cell cancer	4.87e-05	0.000249	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—HRAS—germ cell cancer	4.83e-05	0.000246	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—HRAS—germ cell cancer	4.79e-05	0.000244	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KIT—germ cell cancer	4.69e-05	0.000239	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—FGFR3—germ cell cancer	4.66e-05	0.000238	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	4.62e-05	0.000236	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KITLG—germ cell cancer	4.6e-05	0.000235	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CRABP1—germ cell cancer	4.53e-05	0.000231	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KIT—germ cell cancer	4.5e-05	0.00023	CbGpPWpGaD
Sirolimus—MTOR—Disease—FGF4—germ cell cancer	4.5e-05	0.00023	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AVP—germ cell cancer	4.5e-05	0.00023	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KIT—germ cell cancer	4.48e-05	0.000229	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KIT—germ cell cancer	4.28e-05	0.000219	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FGF4—germ cell cancer	4.24e-05	0.000217	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CRABP1—germ cell cancer	4.16e-05	0.000212	CbGpPWpGaD
Sirolimus—MTOR—Disease—H2AFZ—germ cell cancer	4.02e-05	0.000205	CbGpPWpGaD
Sirolimus—FGF2—Immune System—FGFR3—germ cell cancer	4.01e-05	0.000205	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KITLG—germ cell cancer	4e-05	0.000204	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—germ cell cancer	3.96e-05	0.000202	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—H2AFZ—germ cell cancer	3.79e-05	0.000194	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC2A3—germ cell cancer	3.74e-05	0.000191	CbGpPWpGaD
Sirolimus—FGF2—Disease—FGFR3—germ cell cancer	3.7e-05	0.000189	CbGpPWpGaD
Sirolimus—MTOR—Disease—KITLG—germ cell cancer	3.69e-05	0.000189	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—OXT—germ cell cancer	3.69e-05	0.000188	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC22A3—germ cell cancer	3.69e-05	0.000188	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KIT—germ cell cancer	3.68e-05	0.000188	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—MYC—germ cell cancer	3.62e-05	0.000185	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—HRAS—germ cell cancer	3.55e-05	0.000181	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KITLG—germ cell cancer	3.49e-05	0.000178	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FGFR3—germ cell cancer	3.42e-05	0.000175	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AVP—germ cell cancer	3.41e-05	0.000174	CbGpPWpGaD
Sirolimus—FGF2—Disease—KIT—germ cell cancer	3.4e-05	0.000173	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGF4—germ cell cancer	3.15e-05	0.000161	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KIT—germ cell cancer	3.14e-05	0.00016	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—germ cell cancer	3.09e-05	0.000158	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CRABP1—germ cell cancer	3e-05	0.000153	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FGFR3—germ cell cancer	2.97e-05	0.000152	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—germ cell cancer	2.86e-05	0.000146	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC2A3—germ cell cancer	2.82e-05	0.000144	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—H2AFZ—germ cell cancer	2.81e-05	0.000144	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC22A3—germ cell cancer	2.78e-05	0.000142	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—AVP—germ cell cancer	2.78e-05	0.000142	CbGpPWpGaD
Sirolimus—MTOR—Disease—FGFR3—germ cell cancer	2.75e-05	0.00014	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KIT—germ cell cancer	2.73e-05	0.000139	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—germ cell cancer	2.73e-05	0.000139	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	2.69e-05	0.000137	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—germ cell cancer	2.62e-05	0.000134	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FGFR3—germ cell cancer	2.59e-05	0.000132	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KITLG—germ cell cancer	2.59e-05	0.000132	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AVP—germ cell cancer	2.53e-05	0.000129	CbGpPWpGaD
Sirolimus—MTOR—Disease—KIT—germ cell cancer	2.52e-05	0.000129	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—germ cell cancer	2.47e-05	0.000126	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KIT—germ cell cancer	2.38e-05	0.000121	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—germ cell cancer	2.35e-05	0.00012	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CRABP1—germ cell cancer	2.27e-05	0.000116	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	2.21e-05	0.000113	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—germ cell cancer	2.03e-05	0.000103	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—germ cell cancer	1.95e-05	9.94e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—germ cell cancer	1.94e-05	9.89e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—germ cell cancer	1.93e-05	9.88e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGFR3—germ cell cancer	1.92e-05	9.82e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—germ cell cancer	1.87e-05	9.55e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—germ cell cancer	1.85e-05	9.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KIT—germ cell cancer	1.77e-05	9.02e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC2A3—germ cell cancer	1.74e-05	8.88e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—germ cell cancer	1.73e-05	8.82e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC22A3—germ cell cancer	1.71e-05	8.75e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—germ cell cancer	1.59e-05	8.12e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—germ cell cancer	1.47e-05	7.5e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—germ cell cancer	1.42e-05	7.24e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CRABP1—germ cell cancer	1.4e-05	7.13e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—germ cell cancer	1.39e-05	7.08e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—germ cell cancer	1.36e-05	6.93e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—germ cell cancer	1.31e-05	6.69e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—germ cell cancer	1.18e-05	6.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—germ cell cancer	1.09e-05	5.56e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—germ cell cancer	1.08e-05	5.49e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—germ cell cancer	1.03e-05	5.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—germ cell cancer	9.71e-06	4.96e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—germ cell cancer	7.98e-06	4.07e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—germ cell cancer	7.63e-06	3.9e-05	CbGpPWpGaD
